PDS Biotechnology Announces Oncology Research and Development Day
June 14 2021 - 8:00AM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
cancer immunotherapy company developing novel cancer therapies
based on the Company’s proprietary Versamune® T-cell activating
technology, today announced it will host an Oncology R&D Day
for analysts, investors, and the scientific community on Wednesday,
June 16th.
The research and development day is scheduled to begin at 8:00
am ET on Wednesday, June 16th, 2021. Participants should dial
877-407-3088 (United States) or 201-389-0927 (International) and
mention PDS Biotechnology.
PDS Biotech’s Oncology R&D Day will focus on the Company’s
advancements in its ongoing preclinical and clinical work and will
feature presentations from:
- Dr. Frank Bedu-Addo, President and CEO, PDS Biotech
- Dr. Lauren V. Wood, Chief Medical Officer, PDS Biotech
- Dr. Jeffrey Schlom, Chief of the Laboratory of Tumor Immunology
and Biology, Center for Cancer Research, National Cancer Institute,
National Institute of Health
- Dr. Julius Strauss, Principal Investigator, Laboratory of Tumor
Immunology and Biology, Center for Cancer Research, National Cancer
Institute, National Institute of Health
- Dr. Caroline Jochems, Staff Scientist, Laboratory of Tumor
Immunology and Biology, Center for Cancer Research, National Cancer
Institute, National Institute of Health
A copy of the presentations will be available on June 17th on
the scientific presentations and publications page of PDS Biotech's
website. Registration for PDS Biotech’s Oncology R&D Day is now
open and a live webcast of the event will be available online in
the investor relations section of the company's website at
https://pdsbiotech.com/investors/news-center/events. A replay will
be available on the company website for approximately 90 days
following the webcast.
About PDS BiotechnologyPDS Biotech is a
clinical-stage immunotherapy company with a growing pipeline of
cancer immunotherapies based on the Company’s proprietary
Versamune® T-cell activating technology platform. Versamune®
effectively delivers disease-specific antigens for in vivo uptake
and processing, while also activating the critical type 1
interferon immunological pathway, resulting in production of potent
disease-specific killer T-cells as well as neutralizing antibodies.
PDS Biotech has engineered multiple therapies, based on
combinations of Versamune® and disease-specific antigens, designed
to train the immune system to better recognize disease cells and
effectively attack and destroy them. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Media & Investor Relations Contact:Deanne
RandolphPDS BiotechPhone: +1 (908) 517-3613Email:
drandolph@pdsbiotech.com
Rich CockrellCG CapitalPhone: +1 (404) 736-3838Email:
pdsb@cg.capital
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Mar 2024 to Apr 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Apr 2023 to Apr 2024